Current treatments for hepatitis C virus (HCV) are quite effective, with a cure rate inching toward 100 percent. However, there are certain subpopulations that fail direct-acting antiviral (DAA) therapy and others who have yet to be diagnosed — up to 50 percent of people with the virus, according to some estimates.
“Christina Lindenmeyer, MD
Gastroenterology and Hepatology Fellow at Cleveland Clinic, OH; Member of the AASLD Membership and Mentorship Committee, Social Media and Technology Committee and Young Investigator Task Force”
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) created the Drug-Induced Liver Injury (DILI) Network to collect and analyze cases of severe liver injury caused by prescription drugs, herbal products and supplements.
In the last decade, considerable time and resources have been devoted to hepatitis C research, leading to significant treatment breakthroughs.
Six cutting-edge abstracts will be presented during Sunday afternoon’s AASLD Plenary Session, which will be moderated by AASLD President Anna S. Lok, MD, FAASLD, and AASLD Secretary Kimberly A. Brown, MD, FAASLD.
Four experts will help clinicians take the uncertainty out of the diagnosis and management of incidental liver lesions during Monday’s DDW® Clinical Symposium, Incidental Liver
Expert teams will tackle two of the most controversial topics in hepatology and GI endoscopy during Monday’s AASLD Academic Debates session, providing attendees with a
A recent analysis published in the journal HEPATOLOGY suggests that the global prevalence of nonalcoholic fatty liver disease (NAFLD) is about 25 percent. According to
Welcome to Chicago, IL and Digestive Disease Week® (DDW) 2017! Here you will attend the first and foremost GI event in the world over the next four days. Included
ABIM is inviting Digestive Disease Week® (DDW) 2017 attendees to a focus-group style discovery session in Chicago. During the session, you will discuss what the
